The effectiveness of cyclogest and duphaston in supporting the luteal phase of infertility patients

Comparison of the effectiveness of cyclogest and duphaston in supporting the luteal phase of infertility patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200825048515N32

Enrollment

100

Registered

2021-05-10

Start date

2021-06-22

Completion date

Unknown

Last updated

2021-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Female infertility. Female infertility, unspecified

Interventions

Intervention 1: Intervention first group: patients in this group are treated with dydrogesterone tablets (Duphaston 10 mg) (Abbott Company, Netherlands) every 12 hours for 12 weeks after embryo transf

Eligibility

Sex/Gender

Female

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: Age 40-20 years old History of infertility and candidate for IVF treatment Normal endometrial thickness (7 to 12 mm) Consent to participate in the study

Exclusion criteria

Exclusion criteria: Having pelvic density adhesion Having advanced endometriosis Having genital tuberculosis

Design outcomes

Primary

Measure	Time frame
Clinical pregnancy rate. Timepoint: Five weeks after the start of the intervention. Method of measurement: Vaginal ultrasound of the uterus.;Chemical pregnancy. Timepoint: Two weeks after embryo transfer. Method of measurement: Laboratory kit.;Beta human chorionic gonadotropin(Beta-HCG). Timepoint: Two weeks after embryo transfer. Method of measurement: Blood test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHatav Ghasemi Tehrani

Esfahan University of Medical Sciences

Hatav.tehrani2014@gmail.com+98 31 3620 2020

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026